[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100633203":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":30,"locations":40,"responsibleParty":59,"collaborators":25,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":65,"sex":71,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":25,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":87,"overallStatus":43,"whyStopped":25,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},{"fullName":5,"class":6},"Psychiatric Centre Rigshospitalet","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"semaglutide","EXPERIMENTAL","Wegovy (semaglutide) once-weekly by subcutaneous injection, titrated to a maximum dose of 2.4 mg",[13],"Drug: semaglutide",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo (saline injection)","PLACEBO_COMPARATOR","Saline once-weekly by subcutaneous injection",[19],"Drug: Placebo",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","semaglutide (Wegovy) once-weekly by subcutaneous injection, titrated to a maximum dose of 2.4 mg.",[9],null,{"type":22,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Placebo","once-weekly by subcutaneous injection of saline (BD Posiflush)",[15],[31,36],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},"Maria E Marstrand, MD","CONTACT","+4520896532","maria.erlang.marstrand@regionh.dk",{"name":37,"role":33,"phone":38,"phoneExt":25,"email":39},"Anders Fink-Jensen, MD, DMSc","+4522755843","anders.fink-jensen@regionh.dk",[41],{"facility":42,"status":43,"city":44,"state":25,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Psychiatric Center Copenhagen, Frederiksberg Hospital","RECRUITING","Frederiksberg","2100","Denmark","DK",{"type":49,"coordinates":50},"Point",[51,52],12.53463,55.67938,{"lat":52,"lon":51},[55,58],{"name":56,"role":33,"phone":57,"phoneExt":25,"email":35},"Maria Marstrand E MD, Ph.d.-student, MD","+4529354369",{"name":37,"role":33,"phone":38,"phoneExt":25,"email":39},{"type":60,"investigatorFullName":61,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"SPONSOR_INVESTIGATOR","Anders Fink-Jensen, MD, DMSci","Principal Investigator: Anders Fink-Jensen, MD, DMSc, Professor, Mental Health Service Centre Copenhagen , Frederiksberg Hospital, NP Lab","100633203","phase-2-effect-of-semaglutide-on-cannabis-use-in-adults-with-cannabis-use-disorder-100633203",false,"NCT07523633","Effect of Semaglutide on Cannabis Use in Adults With Cannabis Use Disorder","A Randomized, Double-Blind, Placebo-Controlled Trial of Semaglutide for Reducing Cannabis Use in Adults With Cannabis Use Disorder","HASHTAG","Inclusion Criteria:\n\n1. Informed oral and written consent.\n2. Meets the criteria for cannabis use disorder (CUD) according to DSM-5 or ICD-10.\n3. Currently seeking to cut down or stop cannabis use.\n4. Positive urine test for cannabinoids.\n5. Body mass index (BMI) ≥ 23 kg\u002Fm².\n6. Age 18-70 years.\n7. Recent frequent cannabis use, defined as use on ≥16 days out of the past 28 days.\n8. Cannabis use (smoked, vaped, edibles) equivalent to THC doses of ≥14 grams in the past 28 days before baseline.\n9. Ability to comply with study procedures and follow-up.\n\nExclusion Criteria:\n\n1. Currently meeting non-cannabis\u002Ftobacco substance use disorder (ICD-10 or DSM-5).\n2. Current or past diagnosis of severe psychiatric illness, defined as schizophrenia, bipolar disorder, or other psychoses, within the past five years.\n3. Suicide attempt or suicidal behavior within the past five years.\n4. Severe neurological disorders, including previous severe traumatic brain injury, stroke, or intracranial hemorrhage.\n5. Type 1 diabetes and type 2 diabetes.\n6. Pregnant or potentially pregnant women: Women of childbearing potential (WOCBP) who are pregnant, breastfeeding, planning to become pregnant within the next eight months (including 20 weeks of treatment plus two months after discontinuation of semaglutide), or not using effective contraception throughout the study period. Effective methods include combined hormonal contraception (oral, intravaginal, transdermal), progestogen-only hormonal contraception (oral, implant, injection), intrauterine device\u002Fsystem (IUD\u002FIUS), bilateral tubal occlusion, partner with vasectomy, or sexual abstinence. WOCBP with a measured serum human chorionic gonadotropin (hCG) level \\>3 U\u002FL at inclusion will also be excluded.\n7. Impaired liver function (liver transaminases \\>3 times the upper reference limit)\n8. Impaired renal function (eGFR \\\u003C50 ml\u002Fmin and\u002For plasma creatinine \\>150 µmol\u002FL).\n9. Impaired pancreatic function (past or current acute or chronic pancreatitis and\u002For amylase \\>2 times the upper limit).\n10. History of medullary thyroid carcinoma (MTC) and\u002For family history of MTC and\u002For Multiple Endocrine Neoplasia type 2 (MEN 2).\n11. Heart disease is defined as decompensated heart failure (NYHA class III or IV), unstable angina pectoris, and\u002For myocardial infarction within the past 12 months.\n12. Uncontrolled hypertension (systolic blood pressure \\>180 mmHg, diastolic blood pressure \\>110 mmHg).\n13. Receipt of experimental medication within the past 30 days.\n14. Use of weight-loss medication within the past 3 months.\n15. Hypersensitivity to the active substance or any of the excipients.\n16. For patients undergoing brain scanning only:\n\n    Contraindications to MRI scanning (magnetic implants, pacemaker, claustrophobia, etc.).\n17. Inability to speak and\u002For understand Danish.\n18. Other conditions: Any other condition that, in the investigator's opinion, may interfere with participation in the trial.","ALL","18 Years","70 Years",{"count":75,"type":76},100,"ESTIMATED","INTERVENTIONAL",[79],"PHASE2","The HASHTAG Study is investigating whether the medicine semaglutide can help adults with cannabis use disorder (CUD) reduce their cannabis use. Participants will be randomly assigned to receive either semaglutide or a placebo. The first 50 participants will have functional brain scans (fMRI) to investigate how the brain responds to cannabis-related cues. The main outcome after 20 weeks is whether semaglutide reduces cannabis use compared to placebo. Changes in brain activity in response to cannabis cues will be explored as a secondary outcome.",[82,83,84,85,86],"Cannabis Use Disorder","Cannabis Use Disorders","Cannabis Abuse","Cannabis Dependence","Cannabis Addiction",[88,89,9,90,91,92,93,94,95,96,97,98,99,100],"GLP-1","Glucagon-like peptide 1","fMRI","cannabis","GLP-1 receptor agonist","Randomized Controlled Trial","Double-Blind Method","Placebo-Controlled","Neuroimaging","Brain activity","Cue reactivity","Craving","Drug therapy","2026-05-12",{"date":103,"type":104},"2026-05-14","ACTUAL",{"date":106,"type":104},"2026-04-30",{"date":108,"type":76},"2028-04-30",{"name":61,"class":6},1]